The Life Sciences team advised Nimbus Therapeutics on its $210 million private financing to advance its next wave of tech-enabled small molecule medicines.
The round was co-led by new investor GV (Google Ventures) and existing investors SR One and Atlas Venture, with participation from another new investor that is a U.S.-based life sciences-focused fund as well as existing investors Bain Capital Life Sciences, BVF Partners L.P., Gates Frontier, Lightstone Ventures, Pfizer Ventures, RA Capital Management, and SV Health Investors.
Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases.
The Goodwin team was led by Gaby Morales-Rivera, Bill Collins, Karin Yoo, Pablo Hernandez Romero, Nikki Miller and Montana Vaughn, and included Justin Pierce, Gozde Guckaya, Dan Karelitz and Brad Weber, with invaluable assistance from Rob Intile, Patrick O’Brien, David Lopes and Nathan Needle.
For more details, read the press release and articles in Fierce Biotech, STAT News and The Boston Globe.